These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20107838)

  • 1. (-)-Hinokinin-loaded poly(D,-lactide-co-glycolide) microparticles for Chagas disease.
    Saraiva J; Lira AA; Esperandim VR; da Silva Ferreira D; Ferraudo AS; Bastos JK; E Silva ML; de Gaitani CM; de Albuquerque S; Marchetti JM
    Parasitol Res; 2010 Feb; 106(3):703-8. PubMed ID: 20107838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vivo therapeutic properties of (-)-cubebin and (-)-hinokinin against Trypanosoma cruzi.
    Esperandim VR; da Silva Ferreira D; Rezende KC; Cunha WR; Saraiva J; Bastos JK; e Silva ML; de Albuquerque S
    Exp Parasitol; 2013 Apr; 133(4):442-6. PubMed ID: 23274812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo infection by Trypanosoma cruzi: a morphometric study of tissue changes in mice.
    Esperandim VR; da Silva Ferreira D; Sousa Rezende KC; Cunha WR; Saraiva J; Bastos JK; Andrade E Silva ML; de Albuquerque S
    Parasitol Res; 2013 Jan; 112(1):431-6. PubMed ID: 22837101
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    de Lima RG; Lisoni FCR; Picão TB; Dos Santos FF; Orenha RP; Borges A; Molina EF; Parreira RLT; E Silva MLA; Santos MFC; de Laurentiz RDS
    Nat Prod Res; 2022 Sep; 36(18):4696-4703. PubMed ID: 34736364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones.
    Esperandim VR; da Silva Ferreira D; Saraiva J; Silva ML; Costa ES; Pereira AC; Bastos JK; de Albuquerque S
    Parasitol Res; 2010 Aug; 107(3):525-30. PubMed ID: 20440625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles.
    Panyam J; Dali MM; Sahoo SK; Ma W; Chakravarthi SS; Amidon GL; Levy RJ; Labhasetwar V
    J Control Release; 2003 Sep; 92(1-2):173-87. PubMed ID: 14499195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere.
    Su Z; Sun F; Shi Y; Jiang C; Meng Q; Teng L; Li Y
    Chem Pharm Bull (Tokyo); 2009 Nov; 57(11):1251-6. PubMed ID: 19881277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi.
    de Souza VA; da Silva R; Pereira AC; Royo Vde A; Saraiva J; Montanheiro M; de Souza GH; da Silva Filho AA; Grando MD; Donate PM; Bastos JK; Albuquerque S; e Silva ML
    Bioorg Med Chem Lett; 2005 Jan; 15(2):303-7. PubMed ID: 15603944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(lactide-co-glycolide) microparticles as systems for controlled release of proteins -- preparation and characterization.
    Porjazoska A; Goracinova K; Mladenovska K; Glavas M; Simonovska M; Janjević EI; Cvetkovska M
    Acta Pharm; 2004 Sep; 54(3):215-29. PubMed ID: 15610618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability.
    Péan JM; Venier-Julienne MC; Boury F; Menei P; Denizot B; Benoit JP
    J Control Release; 1998 Dec; 56(1-3):175-87. PubMed ID: 9801441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of gentamicin released from microparticles.
    Blanco-Príeto MJ; Lecaroz C; Renedo MJ; Kunkova J; Gamazo C
    Int J Pharm; 2002 Aug; 242(1-2):203-6. PubMed ID: 12176247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies on the properties of glycyrrhetinic acid-loaded PLGA microparticles prepared by emulsion and template methods.
    Wang H; Zhang G; Sui H; Liu Y; Park K; Wang W
    Int J Pharm; 2015 Dec; 496(2):723-31. PubMed ID: 26581771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo sustained release of adenoviral vectors from poly(D,L-lactic-co-glycolic) acid microparticles prepared by TROMS.
    García del Barrio G; Hendry J; Renedo MJ; Irache JM; Novo FJ
    J Control Release; 2004 Jan; 94(1):229-35. PubMed ID: 14684286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulated release of IdUrd from poly (D,L-lactide-co-glycolide) microspheres by addition of poly (D,L-lactide) oligomers.
    Geze A; Venier-Julienne MC; Saulnier P; Varlet P; Daumas-Duport C; Devauchelle P; Benoit JP
    J Control Release; 1999 Apr; 58(3):311-22. PubMed ID: 10099156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens.
    Kofler N; Ruedl C; Klima J; Recheis H; Böck G; Wick G; Wolf H
    J Immunol Methods; 1996 Jun; 192(1-2):25-35. PubMed ID: 8699019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres.
    Cirpanli Y; Unlü N; Caliş S; Hincal AA
    J Microencapsul; 2005 Dec; 22(8):877-89. PubMed ID: 16423759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo characterization of huperzine a loaded microspheres made from end-group uncapped poly(d,l-lactide acid) and poly(d,l-lactide-co-glycolide acid).
    Gao P; Ding P; Xu H; Yuan Z; Chen D; Wei J; Chen D
    Chem Pharm Bull (Tokyo); 2006 Jan; 54(1):89-93. PubMed ID: 16394556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of topical cidofovir penetration using microparticles.
    Santoyo S; Ga de Jalón E; Ygartua P; Renedo MJ; Blanco-Príeto MJ
    Int J Pharm; 2002 Aug; 242(1-2):107-13. PubMed ID: 12176232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable microparticles for sustained release of a new GnRH antagonist--part I: Screening commercial PLGA and formulation technologies.
    Schwach G; Oudry N; Delhomme S; Lück M; Lindner H; Gurny R
    Eur J Pharm Biopharm; 2003 Nov; 56(3):327-36. PubMed ID: 14602174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
    Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
    Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.